API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
Details:
Roseday CV (rosuvastatin + clopidogrel) is a fixed dose combination which is approved for the treatment of cardiac diseases like heart attack, angina & stroke.
Lead Product(s): Rosuvastatin,Clopidogrel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Roseday CV
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
Rosuzet is a combination of rosuvastatin is an inhibitor of HMG CoA-reductase, the rate-limiting enzyme that converts the precursor of cholesterol and ezetimibe, a sterol transporter, NPC1L1, which is involved in the intestinal uptake of cholesterol.
Lead Product(s): Rosuvastatin,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Rosuzet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023
Details:
Razel (rosuvastatin) is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.
Lead Product(s): Rosuvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Razel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: JB Pharma
Deal Size: $37.9 million Upfront Cash: $37.9 million
Deal Type: Divestment December 14, 2022
Details:
EDP-235 achieved excellent penetration into monocytes and macrophages, including lung AM. EDP-235 has the potential to eliminate viral replication of SARS-CoV-2 in these critical immune cells, thus mitigating macrophage-mediated cytokine storm in high-risk COVID-19 patients.
Lead Product(s): EDP-235,Midazolam,Rosuvastatin
Therapeutic Area: Infections and Infectious Diseases Product Name: EDP-235
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
Apabetalone (RVX000222), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression.
Lead Product(s): Apabetalone,Atorvastatin,Rosuvastatin
Therapeutic Area: Endocrinology Product Name: RVX000222
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
COLSTAT clinical trial (Colchicine/Statin for the Prevention of COVID-19 Complications) will combine two broadly available medications, colchicine and rosuvastatin, to help reduce complications in Covid-19 infected patients.
Lead Product(s): Colchicine,Rosuvastatin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
Under the terms of this agreement, Grünenthal has acquired the exclusive rights to market CRESTOR™ and its second brands in more than 30 European markets.
Lead Product(s): Rosuvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Crestor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Grunenthal
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 10, 2021
Details:
Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. The deal will give Gruenenthal rights to sell Crestor and associated medicines in more than 30 countries in Europe, except the UK and Spain.
Lead Product(s): Rosuvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Crestor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Grunenthal
Deal Size: $350.0 million Upfront Cash: $320.0 million
Deal Type: Divestment December 01, 2020